AtaiBeckley Inc.
Every calculator, already run for ATAI
Open the full toolkit →You have the numbers on ATAI. Get the argument.
A written report on which of these readings actually decide the outcome for AtaiBeckley Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
14 analysts covering ATAIAnalyst Price Target Disagreement for AtaiBeckley Inc.
Wall Street's bull case implies +121% from the current price; the bear case implies +3%. A 118% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
About AtaiBeckley Inc.
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film…
ATAI — frequently asked
Is ATAI a buy right now?
Wall Street's consensus rating on AtaiBeckley Inc. is Hold across 14 analysts, with a mean price target of $9.59 (+32% vs. the current $7.25). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is ATAI's next earnings date?
AtaiBeckley Inc. is next scheduled to report earnings around Aug 13, 2026. A full ATAI research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for AtaiBeckley Inc.?
Analysts covering AtaiBeckley Inc. (ATAI) range from a bear-case target of $7.45 to a bull-case high of $16.00, with a mean consensus target of $9.59 across 8 analysts. The spread of $8.55 (118% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare AtaiBeckley Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For AtaiBeckley Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full ATAI research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on AtaiBeckley Inc., in minutes. 3 free reports included with every account — no credit card required.